Iodine-124
Phase 2Radiopharmaceutical
Iodine-124 is one of 51 small molecule programs targeting Thyroid Carcinoma. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
62 competitors in Thyroid Cancer
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Tafinlar
NovartisApproved
Cabometyx
Bristol-Myers SquibbApproved
Retevmo
Eli LillyApproved
Vitrakvi
BayerApproved
Rozlytrek
RocheApproved
Caprelsa
GGenzyme, a Sanofi Company
Approved
Gemzar
Johnson & JohnsonApproved
Nexavar
BayerPhase 3
Gavreto
RRigel Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Recurrent1 trial
Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iodine-124. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Phase 2[1]
- Company
- SStanford University